SEC Form 4 · accession 0001782135-26-000028
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Johanna Mercier
Officer — Chief Comm & Corp Aff Officer
Period of report
Aug 17, 2026
Accepted (ET)
Aug 18, 2026 · 6:54 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 17, 2026 | M | 23,110 | $66.64 | A | 144,344 | D | |
| Common Stock | Aug 17, 2026 | M | 1,890 | $72.34 | A | 146,234 | D | |
| Common StockF2 | Aug 17, 2026 | S | 16,530 | $137.365 | D | 129,704 | D | |
| Common StockF3 | Aug 17, 2026 | S | 11,470 | $138.0353 | D | 118,234 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F4 | $66.64 | Aug 17, 2026 | M | 23,110 | D | — | Jul 24, 2029 | Common Stock | 23,110 | 0 | D |
| Non-qualified Stock Option (Right to Buy)F4 | $72.34 | Aug 17, 2026 | M | 1,890 | D | — | Mar 10, 2030 | Common Stock | 1,890 | 69,960 | D |
Explanation of responses
- F1The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.
- F2Sale prices for the transactions reported range from $136.74 to $137.73. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
- F3Sale prices for the transactions reported range from $137.75 to $138.36. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
- F4The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.